A complete list of the patient/provider resources can be found here.
Academic Pathologist – Microbiology and Immunology,
Cardiologist, Iowa Health Cardiology;
Primary care physicians, internists, hospitalists, cardiologists, neurologists, anticoagulation and thrombosis specialists, residents, physician assistants, nurses, nurse practitioners, cardiac techs, support staff, and all other interested health professionals.
Atrial fibrillation (AFib) is the most common heart rhythm disorder seen by primary care physicians. AFib affects an estimated 2.7 million people in the United States and the incidence is expected to double within the next forty years. AFib negatively impacts patient’s quality of life and is a major risk factor for stroke. Despite practice guidelines for managing AFib, it’s estimated that two-thirds of AFib-related strokes can be avoided. Gaps exist between the evidence base and clinical practice. Stroke in patients with AFib result in worse outcomes including higher mortality, greater functional impairment and dependency. Although existing guidelines define effective therapeutic strategies for managing AFib to reduce stroke risk, these strategies are frequently underused or inappropriately understood. Both provider and patient knowledge and attitudes play an important role in the success of current strategies to manage AFib to prevent stroke.
Upon conclusion of this educational activity, participants will be able to:
- Describe the incidence and consequences of untreated atrial fibrillation.
- Identify patients for whom antithrombotic management for atrial fibrillation or atrial flutter is appropriate.
- Document the risk of stroke using a validated assessment tool.
- Determine the relative risk and benefit of antithrombotic therapy for a given patient.
- Select the appropriate antithrombotic therapy including the role of newly approved antithrombotic agents.
- Determine which patients are best managed with a rate-control versus rhythm-control strategy.
- Discuss options for maintaining sinus rhythm including anti-arrhythmic drug therapy and the role of ablation.
- Recite emerging therapies for atrial fibrillation and prevention of its complications.
|7:30 a.m.||Registration and Breakfast|
Epidemiology, Natural History and Risk Factors for Atrial Fibrillation
Gary Hoff, DO, FACOI, FACC, Des Moines University
Dr. Hoff indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Recent Insights into the Mechanisms of Atrial Fibrillation
Samuel J. Asirvatham, MD, Cardiology and Vascular Medicine, Mayo Clinic, MN
Dr. Asirvatham indicated he has received an honoraria for consulting with Abiomed, Biotronik, Boston Scientific, Medtronic, Spectranetics, St. Jude, Sanofi‐Aventis, Stereotaxis, Wolters Kluwer, and Elsevier. He is also copatent holder and may receive future royalties from Nevro, Aegis, and ATP.
Working Up the Patient with Newly Diagnosed Atrial Fibrillation
Lisa Benton, NP, CCA, State Representative
Ms. Benton indicated she has no financial relationships to disclose relevant to the content of this CME activity.
Assessing Stroke Risk: Who Needs to be Anticoagulated?
Calvin J. Hansen, MD, Iowa Health Des Moines
Dr. Hansen indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Which Drug for Which Patient? Coumadin or the Newer Agents: Current Status and Review
Trips, Falls, and Spills: The Geriatrician’s Perspective on Anticoagulating
Darrel E. Devick, DO, FACOI, Mercy Capitol Internal Medicine Clinic
Dr. Devick indicated he has no financial relationships to disclose relevant to the content of this CME activity.
|11 a.m.||Panel Discussion and Case Presentations|
Rate Versus Rhythm Control AFFIRMING the Right Choice
Craig B. Clark, DO, FACC, FAHA, FASE, Iowa Health Cardiology; Iowa Chapter of the American College of Cardiology
Dr. Clark indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Antiarrhythmic Drug Therapy in Atrial Fibrillation
Prasad R. Palakurthy, MD, FACC, FHRS,Electrophysiologist, Iowa Health Cardiology
Dr. Palakurthy indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Ablative Therapy for Atrial Fibrillation
Robert H. Hoyt, MD, FACC, FHRS, Electrophysiologist, Iowa Heart Center
Relevant to this CME activity, Dr. Hoyt indicated he has received an honorarium from Medtronic and Boehringer Ingelheim.
What the Provider Needs to Know When Their Patient Returns to the Office After an Ablation
Christopher J. Mcleod, MBChB, PhD, Cardiology and Vascular Medicine, Mayo Clinic, MN
Dr. McLeod indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Recent Advances in Treatment of Atrial Fibrillation: Non-Pharmacological Stroke Prevention
Alexander Mazur, MD, University of Iowa Carver College of Medicine
Dr. Mazur indicated he has no financial relationships to disclose relevant to the content of this CME activity.
|3:10 p.m.||Interactive Patient Cases|
Provider and Patient Resources
Kevin Carnevale, MD, Des Moines University
Dr. Carnevale indicated he has no financial relationships to disclose relevant to the content of this CME activity.
Attendees will be requested to complete a short learner self-assessment survey regarding their present and desired level of ability to administer antithrombotic therapy for patients with AFib. The information will be used to enhance the learning experience. The response, rationale, and references to each answer will be supplied at the educational activity. We thank you in advance for your time.
- Physician – $50
- Non-Physicians- $25
- Students and residents – Free
This activity is funded through an educational grant from Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership to the TEAM-A Collaborative to support activities that improve the treatment of patients with Atrial Fibrillation. The Physicians’ Institute is a member of TEAM-A and retains full control over the distribution of individual grants under this collaborative grant program.
Thank you to St. Jude Medical, Boehringer Ingelheim and Medtronic for their support.
AAMA: 7.0 CEUs, either- Clinical or General.
AAFP: This Live activity, Improving Outcomes in Patient with Atrial Fibrillation: An Update for the Primary Care Physician, with a beginning date of 04/20/2013, has been reviewed and is acceptable for up to 6.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA PRA: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Iowa Medical Society (IMS) through joint sponsorship of Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) and Des Moines University. Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) is accredited by the IMS to provide continuing medical education for physicians.
Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AOA: Des Moines University is accredited by the American Osteopathic Association to present continuing medical education programs for physicians. Des Moines University and the American Osteopathic Association Council on Continuing Medical Education approve this live program for a maximum of 6.5 hours of AOA Category 1-A CME credits.
IBON: Des Moines University Continuing Medical Education (provider #112) is approved by the Iowa Board of Nursing as an accredited provider. This program has been reviewed and approved for 8.0 continuing education contact hours.
Other: Attendees will be given a certificate of participation for a maximum 6.75 continuing education hours.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Disclosure of faculty and commercial sponsor relationships (if any) will be made known at the activity.
Des Moines University (DMU) prohibits discrimination in employment, educational programs, and activities on the basis of race, national origin, color, creed, religion, sex, age, disability, veteran status, sexual orientation, gender identity, or associational preference. The University also affirms its commitment to providing equal opportunities and equal access to University facilities. Individuals with disabilities are encouraged to attend DMU sponsored activities. If you have questions/concerns, please contact the DMU CME office at 515-271-1596 or email@example.com.